Alerts
COVID-19 update
See our updated visitor policy, which allows 1 visitor per patient during exams only and includes masking for all. No visitors are allowed in treatment (applies at all locations). Only exceptions are patients with physical or mental disability.
Skip Navigation

Cancer Center Members Named to National Breast Cancer Clinical Trials Task Force

January 04, 2021

Jamie Wagner, DO, FACOS, FACS, division chief, breast surgical oncology, and Shane Stecklein, MD, PhD, radiation oncologist, have been appointed to the Breast Oncology Local Disease (BOLD) Task Force of the National Cancer Institute (NCI) Breast Cancer Steering Committee (BCSC). Their three-year terms began January 1, 2021.

The BOLD Task Force was established to provide early input into concepts for NCI National Clinical Trials Network (NCTN) phase 2 and 3 studies of localized breast cancer treated with surgery or radiation therapy. Drs. Stecklein and Wagner will serve as early-career investigators representing NCI-funded clinical trials cooperative groups, SWOG and the Alliance for Clinical Trials in Oncology, respectively.

“In this position, I will be able to support clinical trial growth at the NCI, specifically in the area of breast cancer local disease. There is incredible potential for developing clinical trial ideas, and I will be able to advocate for their success,” Dr. Wagner said.

Nearly all treatments used today exist because of clinical trials. BOLD Task Force members have an essential part in advancing studies that improve outcomes for breast cancer patients.

“The BOLD task force plays an important role addressing areas of unmet clinical need and exploring new approaches to disease treatment,” Dr. Stecklein said. “It is an honor to serve and support the prioritization of national breast cancer clinical trials.” 

Explore more news, events and blog